La vendita allo scoperto per Alvotech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Alvotech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Alvotech (NASDAQ:ALVO) Azioni, Report sulle vendite allo scoperto

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

<ul>
<li>Revenue of $1,021.8 Million Grows 0.9% --</li>
<li>-- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance –</li>
<li>– GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges –</li>
</ul>

News

HOLX

Reported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) to report a quarterly loss at 16 cents per share on revenue of $125.53 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Comtech Telecommunications shares gained 3.9% to $4.29 in after-hours trading.</li>
<li>WD-40 Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) posted better-than-expected results for its first quarter and reiterated its FY25 guidance on Friday. WD-40 shares gained 5.5% to $254.00 in the after-hours trading session.</li>
<li>Analysts are expecting KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) to post quarterly earnings at $2.45 per share on revenue of $1.99 billion. The company will release earnings after the markets close. KB Home shares gained 0.1% to $63.25 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Nordstrom Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) said total company net sales rose 4.9%, while comparable sales increased 5.8% for the nine-week holiday period ended Jan. 4. The company also said it sees comparable sales growth of 2.5% to 3.5% versus 52 weeks in fiscal 2023, up from its previous guidance of 1.0% to 2.0% growth. Nordstrom shares gained 0.2% to $24.05 in the after-hours trading session.</li>
<li>Analysts expect ServiceTitan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) to post a quarterly loss at 3 cents per share on revenue of $198.52 million after the closing bell. ServiceTitan shares gained 0.1% to $101.40 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Markets

Trading Ideas

CMTL

TTAN

WDFC

WD-40 Company, KB Home And 3 Stocks To Watch Heading Into Monday

<h3>Companies Reporting Before The Bell</h3>
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $125.53 million. 
<h3>Companies Reporting After The Bell</h3>
• Calamos Glb Total (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGO#NASDAQ">CGO</a>) is estimated to report quarterly earnings at $2.88 per share on revenue of $770.40 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its third quarter. 
• KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) is likely to report quarterly earnings at $2.47 per share on revenue of $1.98 billion. 
• Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $15.04 million. 
• Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) is expected to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

EDUC

Earnings Scheduled For January 13, 2025

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

ALNY

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

<ul>
<li>-- Updating peak systemic&nbsp;mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT&#xAE; (avapritinib) launch and evolving SM prevalence estimates --</li>
<li>&nbsp;-- Expect to achieve $2 billion in AYVAKIT revenue by 2030 --</li>
<li>-- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained&nbsp;tryptase reductions exceeding 80% in Phase 1 healthy volunteer study --</li>
</ul>

BPMC

Reported Earlier, Blueprint Medicines Sees AYVAKIT 2024 Revenue At $475M–$480M (+130% YoY); Projects $4B SM Franchise Opportunity, Targets $2B AYVAKIT Revenue By 2030;

<ul>
<li>– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 –</li>
<li>– Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion –</li>
<li>– Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET –</li>
</ul>

EXEL

Reported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress

Ahead of President Joe Biden&#8216;s departure from office, a U.S. investigation has concluded that China engages in unfair&nbsp;practices to dominate the global&nbsp;shipbuilding industry. 
What Happened: The probe, initiated by&nbsp;U.S. Trade Representative Katherine Tai&nbsp;in April, was requested by the United Steelworkers and other&nbsp;unions under Section 301 of&nbsp;the Trade Act of 1974. This revelation could lead to potential penalties against China, according to&nbsp;Reuters&nbsp;on Monday. 
Investigators found that China uses&nbsp;financial support, barriers for foreign&nbsp;firms, forced technology transfer, and intellectual property theft to gain an advantage in shipbuilding, a source told Reuters. The report also highlights China&#8217;s suppression of labor costs in the maritime and logistics sectors. The findings could lead to&nbsp;tariffs or port fees on&nbsp;Chinese-built vessels.
The report indicates that China&#8217;s share in&nbsp;the $150 billion global shipbuilding&nbsp;market has grown from 5% in 2000&nbsp;to over 50% in 2023, largely due to government subsidies. Meanwhile, U.S. shipbuilders&#8217; market share has fallen below 1%. The U.S. Trade Representative&#8217;s office is expected to release the findings later this week, just before President Biden leaves office on Jan. 20.
This investigation follows previous&nbsp;efforts by the Biden administration&nbsp;to curb China&#8217;s influence through tariffs and export controls. Experts suggest that rebuilding the U.S. shipbuilding industry will require substantial investment and time.
Why It Matters: The U.S. probe into China&#8217;s shipbuilding practices has sparked significant controversy. Last year, the Chinese Ministry of Commerce <a href="https://www.benzinga.com/news/24/04/38312330/mistake-on-top-of-a-mistake-china-slams-us-probe-into-its-maritime-and-shipbuilding-sectors">criticized the investigation</a>, calling it a &#8220;mistake on top of a mistake,&#8221; asserting that China&#8217;s industrial growth is driven by technological innovation and market competition. 
Additionally, China is projected to surpass the <a href="https://www.benzinga.com/news/24/10/41142611/china-set-to-surpass-us-in-advanced-military-manufacturing-by-2035-report">U.S. in advanced technology </a>and military manufacturing by 2035, as reported by the South China Morning Post. Former vice-chairman of the National People&#8217;s Congress, Lu Yongxiang, emphasized that the decline of U.S. manufacturing is irreversible, suggesting a rapidly diminishing competitive edge for the U.S.
Meanwhile, Chinese policymakers are reportedly considering <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42473889/china-eyes-yuan-devaluation-to-counter-trumps-tariffs-will-it-work">allowing yuan devaluation</a> in 2025 to counter the economic impact of Trump&#8217;s proposed potential 60% tariff on Chinese imports.
Read More:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42931758/apple-staring-at-market-share-decline-in-china-amid-declining-iphone-shipments-top-analyst-flags-why-some-models-could-be-face-shipping-momentum-challenges">Apple Staring At Market Share Decline In China Amid Declining iPhone Shipments: Top Analyst Flags Why Some Models Could Be Face Shipping Momentum Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Global

General

US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms

<ul>
<li>2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1</li>
<li>Strong and Growing Demand for Galafold&#xAE; and Pombiliti&#xAE; + Opfolda&#xAE;</li>
<li>Total Revenue Growth of 17-24% at CER Expected in 2025</li>
<li>&gt;3,000 People Treated with an Amicus Therapy Today2</li>
</ul>

FOLD

Reported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales

Financial Update
<ul>
<li>Unaudited preliminary estimate of total full-year 2024 product revenue of ~€226 million:
<ul>
<li>SKYTROFA full-year 2024 revenue expected to be ~€202 million excluding sales deductions related to prior years (based on unaudited preliminary estimate of full-year 2024 SKYTROFA revenue of ~€197 million plus ~€5 million of sales deductions related to prior years).</li>
<li>YORVIPATH full-year 2024 unaudited preliminary revenue estimate of ~€29 million.</li>
</ul>
</li>
<li>Unaudited preliminary estimate of total full-year total 2024 revenue of ~€364 million
<ul>
<li>Includes $100 million Novo Nordisk milestone payment as non-product revenue.</li>
</ul>
</li>
<li>December 31, 2024 pro forma cash balance of ~€655 million (based on unaudited preliminary estimate of December 31, 2024 cash balance of €560 million plus expected payment from Novo Nordisk of $100 million).</li>
</ul>

ASND

Reported Earlier, Ascendis Pharma Projects €364M In 2024 Revenue, Reports €655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

ILMN

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

Arthur Hayes, co-founder of cryptocurrency exchange&nbsp;BitMEX and Chief Investment Officer at&nbsp;Maelstrom&nbsp;Fund, cast aspersions on MicroStrategy Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-powered Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy, forecasting challenging times for the firm when the top cryptocurrency loses volatility.
What happened: In an interview with Benzinga, Hayes slammed MicroStrategy&#8217;s volatility monetization play, which includes issuing convertible debt and other fixed-income securities to buy Bitcoin.
&#8220;The reason why these are attractive instruments is because the stock and the Bitcoin they purchase, are volatile,&#8221; Hayes said. 
Bitcoin has experienced a record-breaking run, rising by almost 50% in the last three months, helped by Donald Trump&#8217;s presidential victory. The rally has caused extreme upside volatility in Michael Saylor&#8217;s MicroStrategy, known more for its Bitcoin portfolio than the core software business. The stock has moved 62% in the last three months.
However, Hayes warned that things may not remain the same. &#8220;When the volatility of Bitcoin declines, most likely after a major crash, it will become difficult for MSTR to attract interest in these types of debt. At that point, the game is up.&#8221;
The Bitcoin bull said he won&#8217;t trade the MSTR stock at all, arguing that there are &#8220;better&#8221; ways to go long or short on Bitcoin.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Why It Matters: Hayes&#8217; remarks added to the growing concerns around MicroStrategy&#8217;s Bitcoin purchases.
Well-known economist Peter Schiff&nbsp;said previously that the company&#8217;s commitment to repay convertible note holders could be at a&nbsp;<a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy" target="_blank" rel="noreferrer noopener">potential risk</a>&nbsp;if Bitcoin drops significantly in value.
Martin Shkreli, known popularly as "Pharma Bro," <a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading">went to the extent of calling </a>the play a &#8220;big bubble," adding that he was short on MicroStrategy.
However, Anthony Scaramucci, CEO of investment firm&nbsp;SkyBridge Capital, has backed the strategy, arguing that the narrative that Bitcoin drops will force the company to liquidate its stash is overblown.
Price Action: At the time of writing, Bitcoin was exchanging hands at $93,573.37, down 0.90% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Shares of MicroStrategy closed 1.14% higher at $327.91 during Friday&#8217;s regular session. The stock has a consensus price target of $449.5 based on ratings by 12 analysts, with an average price target of $546.67 from Bernstein, TD Cowen, and Barclays.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

MSTR

Michael Saylor's MicroStrategy Will Struggle When Bitcoin's Volatility Falls, Says Arthur Hayes — I Would Not Trade MSTR At All

"2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and broadened our clinical stage pipeline," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "In 2025, we are poised to diversify our business further across multiple dimensions: our revenue, as we continue the launches of CASGEVY, ALYFTREK and potentially launch suzetrigine in acute pain; our pipeline, as we progress four potentially transformative medicines through pivotal trials; and our geographic footprint, as we expand both our commercial and clinical presence globally."

VRTX

Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025

<a href="https://www.globenewswire.com/Tracker?data=1RcWcJxSNSnWGASUIcrqEm5wmwbOegir3mS2aQtZmjriBWW6vEqZ7p1UrUtYBYb4OcFxpWZfuHTg3L5BahN98iB5FlLtdfjldpaUgr7jbbPgD_Vw1GEnAo1RH_QIML9nP5OiFLyJ5rGCG4wn7Z1dl3L7EYoDyUm-BtYEcCHd87MyYDRCwW8GgdQZlQgtcFyc1j4KXHxPQJEJwQqbQmQVduIETE2iccxtW9_5Kl5qSUx1T_EBeohyrsma6QVh7-L7GMS0saW-FI6xzsKgX6GSd37ML-qpg6MQjUJF4J1xRDBLhmnt9FoRvR7Ug8HeTrTmgFCk5nmy8f0ZWTwpaH3xzoJqKD2gBI-Avu6-B6kKS7479ZZe9RxIdYrGxHyWhQO7">MaxCyte, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Unaudited Fourth Quarter and Full Year 2024 Results
<ul>
<li>Core revenue in the fourth quarter is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in the fourth quarter of 2023</li>
<li>Core revenue for the full year is expected to be between $32.2 million and $32.4 million compared to $29.8 million for fiscal year 2023, representing 8 to 9% growth</li>
<li>SPL program-related revenue and Total Revenue for the fourth quarter and full year 2024 is expected to be reported in March 2025</li>
</ul>

Guidance

MXCT

MaxCyte Expects Q4 Core Revenue Of $8.3M-$8.5M Vs $7.2M YoY And FY24 Core Revenue Of $32.2M-$32.4M Vs $29.8M YoY

<ul>
<li>2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023</li>
<li>Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023</li>
<li>Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million</li>
</ul>

CSTL

Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments

&nbsp;CME Group, the world's leading derivatives marketplace, today announced that its international average daily volume (ADV) reached a record 7.8 million contracts in 2024, up 14% from 2023.&nbsp;Reflecting all trading reported outside the United States, this was driven by record growth in Energy up 31%, Metals up 27%, Agricultural up 25%, Interest Rate up 12% and Foreign Exchange products up 10% compared to the same period in 2023.

CME Group Hits Record 7.8 Million Daily International Contracts in 2024, up 14% YoY Driven by Energy and Metals Growth

<ul>
<li>Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia</li>
<li>Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing Authorization</li>
<li>Advancing Radiotherapeutic Assets including Alpha- and Auger-emitting Radioconjugates into Phase 1/2a Solid Tumor Studies</li>
</ul>

CLRB

Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development

Reported Earlier, Medical Properties Trust Supports Prospect's Chapter 11 Sale Plans For Connecticut Hospitals

Telix will acquire these assets through an asset purchase agreement with a concurrent technology license agreement to be signed at closing. The purchase price for the transaction is US$45 million (AU$73 million)3, comprised of US$10 million in cash and US$31 million in equity at closing, and a deferred payment of up to US$4 million in equity at the conclusion of a 15-month indemnity period. Upon achievement of specific key development and commercial milestones, Telix will pay up to a total of US$185 million (AU$299 million), a portion of which may be paid in cash or equity at Telix's election4. Royalties are also payable on net sales in the low single digits on a limited number of platform and early-stage products after the first four products have been developed, as well as single-digit sublicense fees, as applicable.&nbsp;&nbsp;

Reported Earlier, Telix To Acquire Imaginab's Drug Candidates And Cutting-Edge Antibody Engineering Platform For $45M

Defense giant Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has donated $1 million to President-elect Donald Trump&#8217;s inaugural committee, maintaining its tradition of inaugural support amid rising competition from technology companies in the defense sector.
What Happened: The donation, made Dec. 2, mirrors Lockheed&#8217;s previous contributions to both Trump&#8217;s 2017 and President Joe Biden&#8216;s 2020 inaugurations, CBS News <a href="https://www.cbsnews.com/news/lockheed-martin-donates-1-million-inaugural-committee/">reported</a> on Friday. The aerospace firm, valued at over $110 billion, reported $67.6 billion in net sales for 2023 under CEO Jim Taiclet.
This contribution comes as Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Anduril Industries <a href="https://www.benzinga.com/markets/equities/24/12/42640010/palantir-and-anduril-reportedly-lead-consortium-partner-with-spacex-and-openai-to-compete-against-traditional-defense-contractors-in-850-billion-us-military-market">reportedly lead a new tech consortium</a>, challenging traditional defense contractors&#8217; grip on the $850 billion U.S. military market. The group, which may include SpaceX and OpenAI, plans to announce formal agreements in January.
Palantir&#8217;s market capitalization has surged to $155 billion, surpassing Lockheed Martin&#8217;s valuation. The data analytics company&#8217;s shares soared more than 50% following Trump&#8217;s election victory, despite a recent 11.78% year-to-date decline.
See Also: <a href="https://www.benzinga.com/25/01/42937761/singapore-restricts-residents-from-using-prediction-platform-polymarket-over-gambling-law-violation">Singapore Cracks Down On Polymarket: Regulator Issues Warning Against &#8216;Illegal Gambling&#8217;</a>
Why It Matters: Adding pressure on traditional contractors, Trump&#8217;s appointed Department of Government Efficiency (DOGE) co-lead, Elon Musk, recently criticized Lockheed&#8217;s F-35 fighter program, advocating for drone warfare over the $1.8 trillion <a href="https://www.benzinga.com/news/24/11/42157649/trumps-doge-co-lead-elon-musk-slams-lockheed-martins-f-35-fighter-jets-advocates-drone-warfare-as-pentagon-defends-1-8-trillion-program">manned aircraft initiative</a>.
The inaugural committee has secured over $170 million for January events, including a reception at the National Gallery of Art and The Starlight Ball at Union Station. Other major tech donors include Meta Platforms Inc., Microsoft Corp., Amazon.com Inc., Alphabet Inc.&#8216;s Google, and Apple Inc.
Wedbush Securities analyst Dan Ives predicts 2025 will be a breakthrough year for tech companies in defense, as the sector increasingly emphasizes AI-powered solutions and autonomous systems over <a href="https://www.benzinga.com/markets/equities/24/12/42696805/palantir-touted-as-next-oracle-by-dan-ives-here-is-why-the-wedbush-analyst-called-the-company-a-table-pounder">traditional military hardware</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/space/25/01/42937555/jeff-bezos-says-he-takes-elon-musk-at-face-value-despite-his-close-ties-to-trump-dismisses-concerns-about-spacex-undercutting-blue-origin">Jeff Bezos Says He Takes Elon Musk At &#8216;Face Value&#8217; Despite His Close Ties To Trump, Dismisses Concerns About SpaceX Undercutting Blue Origin</a></li>
</ul>
Image Via Lockheed Martin
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

PLTR

Lockheed Martin Donates $1M To Trump's Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts

Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 millionAnticipates total
<ul>
<li>Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million</li>
<li>Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023</li>
<li>Plans to launch three new cancer tests in 2025: Cologuard PlusTM, next-generation colorectal cancer screening test, OncodetectTM, molecular residual disease test, and CancerguardTM, multi-cancer screening test</li>
</ul>

EXAS

Reported Earlier, Exact Sciences Reports Preliminary 2024 Results: Expects $2.76B In Annual Revenue (+10% YoY) And $713M In Q4 Revenue (+10% YoY)

Johnson & Johnson: Tracking Well Above The Industry

Alvotech GAAP EPS of -$0.63, revenue of $339M

Alvotech (ALVO) has released an update. Alvotech has reported a significant financial turnaround for the first nine months of 2024, with total reve...

Alvotech Showcases Strong Financial Growth and Expansion

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Alvotech ( ($ALVO) ) has released its Q3 earnings. Here is a breakdown of the information Alvotech presented to its investors. Alvotech is a global...

Alvotech Reports Strong Revenue Growth in 2024

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Alvotech (ALVO – Research Report), with a price target...

Northland Securities Reaffirms Their Buy Rating on Alvotech (ALVO)

Alvotech's Position In The Coming Biosimilar Gold Rush

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00. The c...

Northland Securities Keeps Their Buy Rating on Alvotech (ALVO)

FDA approves Celltrion's biosimilar of J&J's Stelara

Alvotech ( ($ALVO) ) just unveiled an announcement. Alvotech announced its inclusion in the Nasdaq Biotechnology Index, effective December 23, 2024...

Alvotech Joins Nasdaq Biotechnology Index, Boosting Industry Presence

ABBV

ALVO

ALVOW

AMGN

AZNCF

BEIGF

BGNE

BMYMP

LEGN

NVSEF

TEVA

Press Releases

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Health Care

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Comments

Alvotech

Vendite allo scoperto

Alvotech (NASDAQ:ALVO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO